We are live on ! Find out more
ASND icon

Ascendis Pharma A/S
ASND

203 hedge funds and large institutions have $8.28B invested in Ascendis Pharma A/S in 2024 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 75 increasing their positions, 67 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

65% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 23

12% more repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 67

7% more funds holding

Funds holding: 189 → 203 (+14)

6% more funds holding in top 10

Funds holding in top 10: 16 → 17 (+1)

0.19% less ownership

Funds ownership: 105.35% → 105.16% (-0.19%)

10% less capital invested

Capital invested by funds: $9.19B → $8.28B (-$914M)

52% less call options, than puts

Call options by funds: $21.1M | Put options by funds: $43.9M

Holders
203
Holders Change
+14
Holders Change %
+7.41%
% of All Funds
2.93%
Holding in Top 10
17
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+6.25%
% of All Funds
0.25%
New
38
Increased
75
Reduced
67
Closed
23
Calls
$21.1M
Puts
$43.9M
Net Calls
-$22.8M
Net Calls Change
-$19.3M

Top Buyers

1
Westfield Capital Management
Westfield Capital Management
Massachusetts
+$121M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$83.1M
3
Ameriprise
Ameriprise
Minnesota
+$82.4M
4
Fidelity International
Fidelity International
Bermuda
+$58.7M
5
ACA
Avoro Capital Advisors
New York
+$31.3M

Top Sellers

1
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
-$345M
2
Artisan Partners
Artisan Partners
Wisconsin
-$187M
3
Brown Advisory
Brown Advisory
Maryland
-$27.9M
4
TD Asset Management
TD Asset Management
Ontario, Canada
-$18.6M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$18.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
PAMP
126
Polar Asset Management Partners
Ontario, Canada
$899K -$5.1M -37,500 -85%
TRCT
127
Tower Research Capital (TRC)
New York
$885K +$813K +5,975 +1,165%
HT
128
Headlands Technologies
Illinois
$864K +$862K +6,338 New
Susquehanna International Group
129
Susquehanna International Group
Pennsylvania
$861K +$859K +6,313 New
CPIG
130
Chicago Partners Investment Group
Illinois
$834K -$58.9K -433 -7%
SG Americas Securities
131
SG Americas Securities
New York
$833K +$572K +4,205 +221%
ECU
132
Eisler Capital (US)
New York
$829K +$827K +6,080 New
Mackenzie Financial
133
Mackenzie Financial
Ontario, Canada
$725K -$28.3K -208 -4%
GC
134
Gratus Capital
Georgia
$682K – – –
First Trust Advisors
135
First Trust Advisors
Illinois
$673K +$671K +4,932 New
PCM
136
Prelude Capital Management
New York
$645K +$644K +4,730 New
DZ Bank
137
DZ Bank
Germany
$632K +$631K +4,635 New
CM
138
Caption Management
Oklahoma
$627K -$657K -4,826 -51%
HS
139
HighVista Strategies
Massachusetts
$617K – – –
LCM
140
Legato Capital Management
California
$590K +$368K +2,708 +168%
Balyasny Asset Management
141
Balyasny Asset Management
Illinois
$576K +$574K +4,221 New
RJA
142
Raymond James & Associates
Florida
$564K +$408 +3 +0.1%
AAM
143
Advisors Asset Management
Colorado
$525K +$524K +3,848 New
Allianz Asset Management
144
Allianz Asset Management
Germany
$514K +$544 +4 +0.1%
FRM
145
Fox Run Management
Connecticut
$493K +$492K +3,613 New
ProShare Advisors
146
ProShare Advisors
Maryland
$488K -$61.1K -449 -11%
DnB Asset Management
147
DnB Asset Management
Norway
$456K +$455K +3,347 New
Russell Investments Group
148
Russell Investments Group
United Kingdom
$438K – – –
AIM
149
Aigen Investment Management
New York
$431K -$375K -2,753 -47%
Ensign Peak Advisors
150
Ensign Peak Advisors
Utah
$422K -$8.77M -64,453 -95%
4 5
6
7 8

ASND Hedge Fund Activity: Q2 2024 in Review

203 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q2 2024, worth a combined $8.28B — down 9.9% from $9.19B a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new ASND positions and 23 closed out — a net gain of 15 holders — while 75 added to existing stakes and 67 trimmed.

The largest buyer was Westfield Capital Management, adding an estimated $121M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $345M.

  • 203 institutional investors held Ascendis Pharma A/S (ASND) as of Q2 2024, up from 189 in Q1 2024.
  • Funds reported $8.28B of Ascendis Pharma A/S stock for Q2 2024, down 9.9% quarter-over-quarter.
  • 38 funds opened new Ascendis Pharma A/S positions in Q2 2024 and 23 closed out, a net change of +15 holders.
  • The largest Ascendis Pharma A/S buyer in Q2 2024 was Westfield Capital Management, an estimated $121M added.
  • The largest Ascendis Pharma A/S seller in Q2 2024 was T. Rowe Price Investment Management, an estimated $345M sold.

Based on aggregated 13F filings for Q2 2024.